SEC, DOJ subpoena Biogen over Aduhelm launch and foreign business operations

Adding to the mul­ti­ple in­ves­ti­ga­tions in­to Bio­gen and its con­tro­ver­sial Alzheimer’s drug Aduhelm since its ap­proval, the com­pa­ny re­vealed in SEC fil­ings on Wednes­day that it has been sub­poe­naed by both the Se­cu­ri­ties and Ex­change Com­mis­sion and the De­part­ment of Jus­tice.

Ac­cord­ing to Bio­gen, the SEC is­sued a sub­poe­na for in­for­ma­tion re­lat­ed to Aduhelm and its launch, while the DOJ wants in­for­ma­tion on the com­pa­ny’s “busi­ness op­er­a­tions in sev­er­al for­eign coun­tries.” Bio­gen said it’s al­so giv­ing in­for­ma­tion on that same top­ic to the SEC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.